|
|
Article: Bracco Diagnostics Inc. and Lantheus Medical Imaging Enter into Agreement to Co-Promote Bracco's CardioGen-82(R) (Rubidium Rb 82 Generator).
- Article from:
- Business Wire
- Article date:
- September 23, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Only FDA-approved Generator-based PET Perfusion Agent Reimbursed for Evaluation of Coronary Artery Disease
PRINCETON, N.J. & N. BILLERICA, Mass. -- Bracco Diagnostics Inc., the US-based subsidiary of Bracco Imaging SpA and part of the Bracco Group, and Lantheus Medical Imaging, Inc., both worldwide leaders in diagnostic imaging, announced today that the companies have entered into an agreement for Lantheus to co-promote Bracco's CardioGen-82[R] (Rubidium Rb 82 Generator), a myocardial perfusion Positron Emission Tomography (PET) imaging agent. CardioGen-82 is the only generator-based PET perfusion agent approved by the U.S. Food and Drug Administration (FDA) and ...
Related newspaper, magazine, and journal articles:
|
|
Article: EPIX Pharmaceuticals Announces Sale of U.S., Canadian and ...
Business Wire;
April 7, 2009 ;
700+ words
... ... angiography (MRA) agent, to Lantheus Medical Imaging, Inc. for aggregate ... chief executive officer of Lantheus Medical Imaging, Inc. "We believe the ... Foundation Therapeutics. About Lantheus Medical Imaging, Inc. Lantheus Medical ...
|
|